For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

There is no FDA-approved generic therapeutic equivalent.

  • Active against common bacterial eye pathogens, including Staphylococcus aureus and Staphylococcus
    (including penicillin-resistant isolates), and some Streptococcus pneumoniae2
  • Contains ½ the concentration of dexamethasone compared to generic
    tobramycin/dexamethasone ophthalmic suspension formulations3
  • Power of an anti-inflammatory and anti-infective in each drop2
  • Eligible patents pay as little as $40 with the copay savings card.

*This offer is not valid for patients who are enrolled in Medicare Part D, Medicaid, Medigap, VA, DOD, TriCare, or any other
government-run or government sponsored healthcare program with a pharmacy benefit. See program materials for additional
eligibility requirements and complete terms and conditions.

Click here for full prescribing information
Click here for the copay savings voucher

TOBRADEX® ST ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant isolates. Streptococci, including some Group A and other beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris isolates, Haemophilus influenzae, H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
Dosing and Administration
  • Instill one drop into the conjunctival sac(s) every 4 to 6 hours.
  • During the initial 24 to 48 hours, dosage may be increased to one drop every 2 hours.
  • Frequency should be decreased gradually as warranted by improvement in clinical signs, but care should be taken not to discontinue therapy prematurely.


  • TOBRADEX® ST Suspension, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Hypersensitivity to any component of the medication.

Warnings and Precautions:
  • Intraocular pressure (IOP) increase — Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If used for 10 days or longer, IOP should be monitored.
  • Sensitivity to topically applied aminoglycosides may occur.
  • Cataracts — Use of corticosteroids may result in posterior subcapsular cataract formation.
  • Delayed healing — The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Bacterial infections — Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
  • Viral infections — Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections — Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
  • If used in combination with systemic aminoglycoside antibiotics, the patient should be monitored for total serum concentration of tobramycin.

Adverse Reactions:
Most common adverse reactions to topical ocular tobramycin occurring in less than 4% of patients are hypersensitivity and localized ocular toxicity, including eye pain, eyelid pruritus, eyelid edema, and conjunctival hyperemia. The reactions due to the steroid component are increases in intraocular pressure with possible development of glaucoma.

For additional information about TOBRADEX® ST Suspension, please click here to view the full prescribing information.

References: 1. There is no FDA-approved therapeutic equivalent version of TOBRADEX® ST Suspension. Drugs@FDA entry for "Tobradex ST Suspension," available at Accessed December 5, 2011. 2. TOBRADEX® ST Suspension package insert. 3. Scoper SV, Kabat AG, Owen GR, et al. Ocular distribution, bactericidal activity and settling characteristics of TOBRADEX® ST ophthalmic suspension compared with TobraDex® ophthalmic suspension. Adv Ther. 2008;25(2):77-88.

      ©2015 Novartis      4/15      TDX15005WB

Copyright © 2012 Novartis, a global company based in Basel, Switzerland. The information and materials within this section pertain to the U.S. market only. Not all products are approved in every market, and approved labeling and instructions may vary by local country. See Alcon Privacy Policy and Terms & Conditions for use of this site.

Other Alcon informational Websites:
Glaucoma Eye Vitamins Allergy Eyes Nasal Allergies Ear Infection Treatment Cataract Surgery Refractive Surgery Intraocular Lens Contact Lens Solution